1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ViewRay, Inc.

ViewRay, Inc.

VRAYQ
ViewRay, Inc.US flagOther OTC
0.00
USD
+0.00
- -
18,340.00Market Cap
2013 Y
2013 Y
2014 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
3.87
- -
- -
0.6
0.55
0.58
1
0.86
0.39
0.43
0.57
0.58
Basic EPS, GAAP
- -
-34.59
-0.01
- -
-2.58
-1.26
-1.23
-0.94
-1.18
-0.73
-0.67
-0.59
-0.61
Free Cash Flow per Basic Share
- -
-33.2
-0.01
- -
-2.53
-0.88
-1.24
-1.55
-0.86
-0.47
-0.39
-0.53
-0.64
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
-11.28
-6.17
-5.46
-4.91
-5.08
-4.23
-4.47
-4.66
-4.81
Tangible Book Value per Share
- -
- -
- -
- -
-0.41
-1.09
0.03
2.06
2.12
0.88
1.03
0.45
0.3
Basic Weighted Avg Shares
- -
1
4
1
17
40
58
81
102
148
165
181
181
Sales/Revenue/Turnover
- -
3
- -
- -
10
22
34
81
88
57
70
102
106
Operating Margin (%)
- -
-857.77
- -
- -
-398.72
-198.66
-141.48
-92.75
-137.61
-185.87
-147.82
-103.04
-101.52
Depreciation Expense
- -
1
- -
- -
1
2
2
3
5
6
6
5
5
Net Income, GAAP
- -
-27
- -
- -
-45
-51
-72
-76
-120
-108
-110
-107
-110
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-861.73
- -
- -
-433.06
-227.71
-212.02
-94.36
-136.93
-189.26
-156.94
-105.01
-104.3
Working Capital
- -
- -
- -
- -
15
-1
66
224
253
168
207
132
27
LT Debt
- -
- -
- -
- -
29
44
45
55
64
66
62
84
4
Total Equity
- -
- -
- -
- -
-7
-44
2
167
216
130
170
82
55
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-1,862,000.66
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
3
3
81
LT Borrowings
59
78
- -
LT Finance Leases
6
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
181
182
183
Market Capitalization
648
809
627

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
222
228
194
Cash, Cash Equivalents & STI
142
136
81
Accounts Receivable, Net
29
41
48
Inventories
31
31
42
Total Current Liabilities
83
97
167
Payables & Accruals
38
52
45
ST Debt
3
3
81
Deferred Revenue
42
41
40

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1,657.69%
-51.56%
Free Cash Flow
- -
13.01%
50.21%
Net Income, GAAP
- -
10.49%
-2.47%
Sales/Revenue/Turnover
- -
35.99%
45.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
16
15
19
20
70
2022
19
22
26
35
102
2023
23
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.17
-0.19
-0.15
-0.16
-0.67
2022
-0.14
-0.15
-0.14
-0.15
-0.59
2023
-0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Paul Ziegler Jr.
Full Time Employees
295
Sector
Healthcare
Industry
Medical - Devices
Address
1099 18th Street Denver CO United States of America 80202
IPO Date
Aug 10, 2015
CIK
0001597313
Website
viewray.com
Similar Companies
AViTA Corporation (4735.TWO)
Viemed Healthcare, Inc. (VMD.TO)
CONMED Corporation (CNMD)
Creo Medical Limited (CREO.L)
Holdco Nuvo Group D.G Ltd. Warrants (NUVOW)
GN Store Nord A/S (GNNDY)
Business
ViewRay, Inc. (OTC:VRAYQ) designs, manufactures, and markets magnetic resonance imaging (MRI)-guided radiation therapy systems for imaging and treating cancer patients. The company offers the MRIdian system, including the MRIdian A3i model featuring diagnostic-quality MRI imaging, real-time tissue tracking, automated beam gating in up to three planes, automated contouring and adaptation tools, patient breath-hold display, and brain treatment capabilities with dedicated coils and immobilization; MRIdian supports personalized treatments for pancreas, prostate, lung, liver, breast, and oligometastatic cancers while addressing beam distortion, skin toxicity, and soft-tissue visualization limitations of conventional systems. ViewRay serves university research hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through direct sales and distributors in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. Founded in 2004 and headquartered in Denver, Colorado, with prior principal offices in Oakwood Village, Ohio, the company operates in the radiation oncology segment of the medical technology industry, targeting oncologists and radiation therapy providers. In July 2023, ViewRay and certain subsidiaries filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the District of Delaware to pursue a sale of all or a portion of its assets while supporting customers with $6 million in debtor-in-possession financing from MidCap Financial Services and existing cash reserves; reorganization efforts failed, leading to cessation of operations effective October 25, 2023. The company conducted workforce reductions, including over 100 layoffs in 2023, terminated its CEO, interim CFO, and chief legal officer, and delisted from Nasdaq to OTC trading under VRAYQ amid ongoing adversary proceedings as of 2025. ViewRay Systems, Inc. maintains the MRIdian website promoting A3i installations, patient treatments across multiple disease sites, and clinical evidence of reduced side effects and extended survival, though no acquisition or emergence from bankruptcy is confirmed.